At a glance
ClinicalIndex Comparison RecordPhase 3Unknown· 346 target
Drug / intervention
Sorafenibdrug
Likely dose
Sorafenib 400 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Sorafenib Maintenance for Prophylaxis of Leukemia Relapse in Allogeneic Hematopoietic Stem Cell Transplant Recipients With FLT3 Negative Acute Leukemia
Nanfang Hospital, Southern Medical University·interventional·Posted Dec 19, 2020·Updated Nov 8, 2021
In Brief
A Phase 3 clinical trial evaluating Sorafenib for Acute Leukemia and 2 related conditions. Targeting 346 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the efficacy and safety of sorafenib maintenance after allo-HSCT in FLT3-negative acute leukemia patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesChina
CollaboratorsPeking University People's Hospital, Xiangya Hospital of Central South University, Zhujiang Hospital, Third Affiliated Hospital, Sun Yat-Sen University, First People's Hospital of Chenzhou, The First Affiliated Hospital of Guangzhou Medical University, The Third Xiangya Hospital of Central South University, Second Affiliated Hospital, Sun Yat-Sen University, The Seventh Affiliated Hospital of Sun Yat-sen University
Timeline
Phase 3UnknownOverdue
202120222023202420252026
Enrollment StartDec 2020
First PostedDec 2020
Primary CompletionDec 2022
Study CompletionDec 2023
TodayJul 2026
First PostedDec 19, 2020
Enrollment StartDec 15, 2020
Primary CompletionDec 31, 2022
Study CompletionDec 31, 2023
TodayJul 1, 2026
Enrollment to primary: 2.0 yearsPosted 5.5 years ago
Interventions
Sorafenibdrug
The initial dose of sorafenib is 400 mg orally twice daily and is adjusted in case of suspected toxicity (dose range, 200-800 mg daily).